Lts Lohmann Therapie-systeme Ag

Lts Lohmann Therapie-systeme Gmbh

Other

Merck Patent Gmbh

Frank Seibertz

Reinhold Meconi

Gabriel Wauer

Thomas Hille

Tina Rademacher

Michael Horstmann

Markus Krumme

Klaus Schumann

Christian Von Falkenhausen

Petra Brandt

Rainer Lichtenberger

Peter Steinborn

Petra Botzem

Shu-Lun Weinheimer

The present invention relates to a transdermal therapeutic system (TTS) comprising an active agent-containing layer structure comprising A) a backing layer and B) a biphasic matrix layer, the biphasic matrix layer having a) a continuous, outer phase having a composition comprising 70 to 100% by weight of at least one polymer, b) a discontinuous, inner phase having a composition comprising the active agent and a dissolver for the active agent in amount sufficient so that the active agent forms a solution with the dissolver in the inner phase and c) an emulsifier in an amount of 0.1 to 20% by weight based on the biphasic matrix layer, processes of manufacture and uses thereof, corresponding methods of treatments therewith.

Transdermal delivery system including an emulsifier

Disclosed are stable dosage forms for oral administration of active pharmaceutical ingredients in which any unpleasant taste sensation, caused by release of the active pharmaceutical ingredient and/or of the excipients in the oral and pharyngeal cavity of the patient, is masked by the use of theobromine-free cocoa.

Oral dosage form containing theobromine-free cocoa

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of solifenacin.

Transdermal therapeutic system for the transdermal administration of solifenacin

The invention relates to transparent therapeutic systems (TTS) which contain the active substance nicotine and which further contain at least one acid amide group as a lateral functional group. The TTS can be transparent and for discreet use. The invention also relates to methods for producing these TTS, said TTS being produced by methods using said polymers and being charged with active substance by way of a printing method.

Nicotine-containing transparent transdermal therapeutic system

A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance. This mixture forms dispersed deposits in the pressure-sensitive adhesive. The buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.

Buprenorphine transdermal delivery system

The invention relates to a mucoadhesive medicinal preparation for administering active substances in veterinary or humane medicine, containing at least one active substance, which preparation is characterized in that it is a mucoadhesive matrix disintegratable in aqueous media, which matrix contains at least one matrix-forming polymer and wherein at least one active substance is dissolved or dispersed, and in that the said preparation disintegrates or erodes within maximally 15 minutes after introduction in an aqueous medium or in body fluids, or in that the preparation initially gels within maximally 15 min after its introduction in an aqueous medium or in body fluids, and disintegrates or erodes within maximally 30 min after said introduction.

Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine

The invention relates to thin film-shaped or wafer-shaped pharmaceutical preparations for oral administration of active substances. The preparations contain at least one matrix-forming polymer which has at least one active substance and at least one carbon dioxide-forming substance dissolved or dispersed therein.

Film-shaped or wafer-shaped pharmaceutical preparation with masked taste

The invention relates to a process for producing hot-seal packs, in particular for transdermal therapeutic systems, by welding to one another, at predetermined linear regions and at polymer layers facing towards one another, two laps of continuous pack material composed of two or more layers. To this end, one (or two) sealing tool(s) are used to bring the pack material into contact with pressure and heat. To improve the quality of the welded seams without altering the cycle rate, according to the invention the sealing time is doubled and the temperature of the sealing tool(s) ( ) is reduced so that there is a considerable reduction in the temperature reached within the pack material ( ), this temperature then being only slightly above the melting point of the polymer used. An example of a sealing tool ( ) is given (FIG. ).

Method for producing heat bonded packages and tool for implementing said method

An active-substance-containing transdermal therapeutic system for the controlled release of estradiol or its pharmaceutically acceptable able derivatives alone or combined with gestagens consisting of a layer, an active-substance-containing reservoir which is bonded thereto and produced by using pressure sensitive adhesives, and a removable protective layer is characterized by the fact that the pressure sensitive adhesive comprises esters of colophony.

Transdermal therapeutic system containing estradiol

An active compound-containing patch for the controlled delivery of oestradiol or its pharmaceutically acceptable derivatives, alone or in combination with gestagens, to human or animal skin, having an active compound-containing reservoir based on ethylcellulose and contact adhesives comprising adhesive resins is characterized by a contact adhesive having a high plasticizer content.

Transdermal, hormone-delivering therapeutic system

Process for the production, transport and storage of a therapeutic system which is in the form of a plaster and has an active layer supersaturated with active ingredient and containing the active ingredient in homogeneous dispersion or in solution, characterized in that it is carried out avoiding process parameters which favour or induce crystallization of active ingredient, and any type of pressure operating on the plaster and, in particular, on the active layer is avoided while it is carried out.

Method for producing a therapeutic system in the form of plaster

An active-substance-containing transdermal therapeutic system for the controlled release of estradiol or its pharmaceutically acceptable derivatives alone or combined with gestagens consisting of a backing layer, an active-substance-containing reservoir which is bonded thereto and produced by using pressure sensitive adhesives, and a removable protective layer is characterized by the fact that the pressure sensitive adhesive comprises esters of colophony.

Growing community of inventors

Rheinbrohl, Germany

Frank Seibertz